Trade Mark Journal No.2025/034 22 August 2025

UK00004249288 14 August 2025 (5)

ADWISPO

International priority date claimed: 14 February 2025 (United States of America) (99042193)

Class 5: Pharmaceutical preparations for the treatment and prevention of obesity, cardiovascular diseases, central nervous system diseases, metabolic disorders, stroke, cancer, inflammatory diseases, respiratory diseases, infectious diseases, auto-immune diseases, solid organ transplant rejection, autoinflammatory disease, blood disease, multiple sclerosis, ulcerative colitis, cystic fibrosis, arthritis, and musculoskeletal and skin disease; antivirals; antibodies for medical purposes; biological preparations for the treatment of cancer; anticoagulants; stem cells for medical purposes; radio-pharmaceutical preparations for the treatment of cancer and solid tumors; diagnostic radio-pharmaceutical preparations; diagnostic preparations for medical purposes.

Bristol-Myers Squibb Company

Representative: Sipara Limited